Skip to main content

IDWeek 2024 Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

Dale N. Gerding, MD

Research Physician
Edward Hines, Jr. Veterans Affairs Hospital

Disclosure(s): AstraZeneca: Advisor/Consultant; Destiny Pharma: Advisor/Consultant, Licensed IP to Destiny; Sebela: Advisor/Consultant, Licensed IP

Poster(s):

(P-193) Risk Factors Associated with Patients Diagnosed with Clostridioides difficile Infection with no Documented Antibiotic Exposures

Thursday, October 17, 2024
12:15 PM - 1:30 PM US PT
(P-194) Evolution of Clostridioides difficile Antimicrobial Susceptibility within the epidemic REA Group BI (RT027) and the endemic REA group Y (RT014/020)

Thursday, October 17, 2024
12:15 PM - 1:30 PM US PT
(P-195) Clinical Clostridioides difficile Diagnostic Test Types and Results are Associated with the Likelihood of Recovering C. difficile in Stool Cultures

Thursday, October 17, 2024
12:15 PM - 1:30 PM US PT
(P-196) Differences in Clostridioides difficile Molecular Epidemiology and Antimicrobial Susceptibility at Two Veterans Affairs Hospitals

Thursday, October 17, 2024
12:15 PM - 1:30 PM US PT